Shigella Diarrhoea Prophylaxis Market Report 2026

Shigella Diarrhoea Prophylaxis Market Overview

• Shigella Diarrhoea Prophylaxis market size has reached to $2.12 billion in 2025 • Expected to grow to $3.11 billion in 2030 at a compound annual growth rate (CAGR) of 7.9% • Growth Driver: Increasing Hygiene And Sanitation Awareness Fueling The Growth Of The Market Due To Rising Efforts To Prevent Disease Transmission • Market Trend: Advancements In Vaccine Technology Driving Progress In Shigella Diarrhoea Prevention • North America was the largest region in 2025.

What Is Covered Under Shigella Diarrhoea Prophylaxis Market?

Shigella diarrhoea prophylaxis refers to the preventive measures taken to reduce the risk of infection caused by Shigella bacteria, which are responsible for causing acute diarrhoeal illness. This form of prophylaxis focuses on interrupting the transmission of the pathogen through improved sanitation, personal hygiene practices, safe handling and consumption of food and water, and public health interventions. The main types of shigella diarrhoea prophylaxis include vaccination, antibiotic prophylaxis, public health measures, and hygiene education. Vaccination refers to the administration of a vaccine to stimulate an individual's immune system to recognize and fight specific pathogens. It can be administered through oral, parenteral, and other routes and is used by various end-users such as healthcare facilities, travel clinics, pharmacies, and government health programs.

What Is The Shigella Diarrhoea Prophylaxis Market Growth Forecast?

The shigella diarrhoea prophylaxis market size is expected to see strong growth in the next few years. It will grow to $3.11 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to development of new oral and injectable vaccines, expansion of global immunization programs, rising government initiatives for public health, adoption of advanced hygiene education programs, integration of digital surveillance and outbreak tracking systems. Major trends in the forecast period include increased adoption of oral and injectable vaccines, rising implementation of antibiotic prophylaxis programs, expansion of community health campaigns and public awareness initiatives, focus on water, sanitation, and waste management improvements, growing hygiene education and safe food handling practices.

Global Shigella Diarrhoea Prophylaxis Market Segmentation

1) By Type: Vaccination, Antibiotic Prophylaxis, Public Health Measures, Hygiene Education 2) By Route of Administration: Oral, Parenteral, Other Administrations 3) By End User: Healthcare Facilities, Travel Clinics, Pharmacies, Government Health Programs Subsegments: 1) By Vaccination: Oral Vaccines, Injectable Vaccines, Combination Vaccines 2) By Antibiotic Prophylaxis: Ciprofloxacin, Azithromycin, Ceftriaxone, Ampicillin, Levofloxacin 3) By Public Health Measures: Water And Sanitation Improvements, Improved Waste Management, Community Health Campaigns 4) By Hygiene Education: Handwashing Campaigns, Safe Food Handling And Preparation Practices, Personal Hygiene Education, Public Awareness Programs

What Is The Driver Of The Shigella Diarrhoea Prophylaxis Market?

The increasing awareness of hygiene and sanitation is expected to propel the growth of the shigella diarrhoea prophylaxis market going forward. Hygiene and sanitation refer to the actions and environmental conditions that promote health and reduce disease transmission through cleanliness and proper waste management. The rise in hygiene and sanitation is driven by increasing awareness of health risks, with more people recognizing the importance of cleanliness in preventing the spread of infectious diseases. Awareness of hygiene and sanitation supports Shigella diarrhoea prophylaxis by reducing person-to-person transmission, as individuals who understand and practice proper handwashing and waste disposal significantly lower the risk of spreading the bacteria in communities. For instance, in March 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, 57% of the global population, or 4.6 billion people, had access to safely managed sanitation services. Among them, 33%, or 2.7 billion people, used private sanitation facilities connected to sewers where the wastewater was treated, while 21%, or 1.7 billion people, used toilets or latrines that safely disposed of waste on-site. Therefore, the increasing awareness of hygiene and sanitation will fuel the growth of the shigella diarrhoea prophylaxis industry.

Key Players In The Global Shigella Diarrhoea Prophylaxis Market

Major companies operating in the shigella diarrhoea prophylaxis market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Viatris Inc., Chongqing Zhifei Biological Products Co. Ltd., Macleods Pharmaceuticals Limited, Alkem Laboratories Limited, Alembic Pharmaceuticals Limited, Vaxcyte Inc., Valneva SE, Sanaria Inc., Intravacc B.V., LimmaTech Biologics AG, Intralytix Inc., Immuron Limited, Institut Pasteur, Hetero Drugs Limited, Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals (Johnson & Johnson), Sanofi Pasteur, Biological E Limited, Sinovac Biotech Ltd., Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL), Emergent BioSolutions Inc., Codagenix Inc., Indian Immunologicals Limited.

Global Shigella Diarrhoea Prophylaxis Market Trends and Insights

Major companies operating in the shigella diarrhoea prophylaxis market are focusing on developing advanced solutions, such as tetravalent bioconjugate shigellosis vaccines, to enhance immune response. Tetravalent bioconjugate shigellosis vaccines are advanced vaccines designed to protect against four major Shigella serotypes by linking bacterial polysaccharides to a carrier protein to enhance immune response. For instance, in November 2024, Valneva SE, a France-based biotech company, and LimmaTech Biologics AG, a Switzerland-based clinical-stage biotech firm, decleared the first participant has been vaccinated in a Phase 2 infant safety and immunogenicity study of Shigella4V2 (S4V2), which is currently the world’s most clinically advanced tetravalent bioconjugate vaccine candidate targeting shigellosis. This marks a significant milestone in the global effort to develop a vaccine against Shigella, a major cause of severe diarrheal disease in children. S4V2 will undergo testing for safety and preliminary efficacy in around 120 healthy adults aged 18 to 50 who have not previously been exposed to Shigella at three locations in the United States

What Are Latest Mergers And Acquisitions In The Shigella Diarrhoea Prophylaxis Market?

In August 2024, Valneva SE, a France-based specialty vaccine company, partnered with LimmaTech to accelerate the development of the advanced tetravalent shigella vaccine candidate. The partnership enables Valneva to advance a promising program addressing a critical unmet medical need. It also highlights LimmaTech’s expertise in vaccine development and their ability to rapidly accelerate program progress. LimmaTech is a Switzerland-based company developing a tetravalent shigella vaccine candidate.

Regional Insights

North America was the largest region in the shigella diarrhoea prophylaxis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Shigella Diarrhoea Prophylaxis Market?

The shigella diarrhoea prophylaxis market consists of revenues earned by entities by providing services such as water quality testing, educational campaigns, infection control consulting, and food safety services. The market value includes the value of related goods sold by the service provider or included within the service offering. The shigella diarrhoea prophylaxis market also includes sales of hand sanitizers, antibacterial soaps, disinfectants, and surface cleaner. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Shigella Diarrhoea Prophylaxis Market Report 2026?

The shigella diarrhoea prophylaxis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the shigella diarrhoea prophylaxis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.